Nanomedicine is big business, getting bigger.

Report: Nanomedicine Market to Surpass $160 Billion by 2015

Nanomedicine represents a principal domain of nanotechnology that offers capability to significantly change the course of treatment for life-threatening diseases. According to Global Industry Analysts Inc., a San Jose, Calif.-based publisher of market research studies, nanomedicine, unlike other therapies, enhances efficacy and significantly minimizes adversities associated with standard therapeutics. And, as GIA makes clear in its new, 698-page study, "Nanomedicine: A Global Strategic Business Report," the technology is big business, expected to exceed $160 billion in the next six years.

The report notes that the application of nanotechnology in the form of nanomedicine in areas including nano drug delivery, nanoanalytical contrast reagents, nanobiomaterials, and nanopharmaceuticals has been surging at a stable rate. Recent years have seen implementation of several programs by the industry to bridge the gap between outcomes of clinical research and commercial products. As a result, the present nanobiomaterial product pipeline poses a healthy picture with numerous novel products for use in health care applications, primarily in the form of coatings. Looking ahead, research and development in the nanomedicine market is expected to offer several novel products that can effectively improve the health of patients suffering from health disorders and illnesses, the report says.

According to the report, the drug delivery market represents the largest application area, while the biomaterials segment represents the fastest-growing application segment for nanomedicine over the years 2006 through 2015. The report notes, however, that the nanomedicine market is highly fragmented and is characterized by the presence of several key and niche players. Major market participants in the nanomedicine market include Abraxis BioScience Inc., AMAG Pharmaceuticals Inc, Arrowhead Research Corp., Crucell N.V., Flamel Technologies S.A., Elan Corporation Plc, Enzon Pharmaceuticals Inc., Life Technologies Corp., Nanosphere Inc., Nektar Therapeutics, Novavax Inc., Oxonica Plc, Par Pharmaceutical Companies Inc., Starpharma Holdings Limited, and Wyeth Pharmaceuticals Inc., among others.

The "Nanomedicine" report covers major market dynamics, trends, issues, and competition pertaining to the market, presenting analytical estimates and projections on market size in terms of dollar sales over the time period 2006-2015. The report enumerates recent developments, mergers, acquisitions, and other strategic industry activities, analyzing the nanomedicine market by the following application areas: Drug Delivery, In Vitro Diagnostics, In Vivo Imaging, Biomaterials, and Other Applications. For more information and purchasing, go to www.strategyr.com/Nanomedicine_Market_Report.asp.

Download Center

HTML - No Current Item Deck